VolitionRx CEO buys 110k shares at $0.51; adds warrants
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
VolitionRx Ltd (VNRX) President & CEO Cameron John Reynolds, also a director, reported buying 110,000 common shares at $0.51 each and acquiring 110,000 warrants for $0.01 apiece, in connection with an underwritten public offering that closed on October 14, 2025.
The warrants are exercisable at $0.60 and expire on October 14, 2030. Following these transactions, he directly owns 2,534,847 common shares, with additional indirect holdings of 1,007,718 shares via Concord International, Inc. and 34,076 shares held by his spouse.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrant (Right to Buy) | 110,000 | $0.01 | $1K |
| Purchase | Common Stock | 110,000 | $0.51 | $56K |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant.
- F2. The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.
AI-generated analysis. How Rhea-AI works. Not financial advice.